3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA. Members of the Artiva management team will also be available to participate in meetings with investors who are registered to attend the conference. To access the audio webcast and subsequent archived recording of this and other company present

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation. "We are delighted to welcome Thad to Artiva as he brings strong late-stage development and comme

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis. "We are thrilled to welcome Elaine to Artiva's board at such an imp

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL). The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings: Post

– 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding – Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials     COVENTRY, England, Jan. 8, 2026 /PRNewswire/ -- NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, today announced the appointment of Thomas J. Farrell as Chief Executive Officer and Director. Tom succeeds company founder Joe Healey, who will remain involved in the company, ensuring continuity and o

32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were treated in community rheumatology trial sites with no specialized oncology oversight, demonstrating the feasibility of administering this regimen outside the hospital setting No cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) Consistent and complete B-cell depletion was observed in all patients with autoimmune disease treated with AlloNK + mAb by Day 13 of treatment, consistent with the experience for AlloNK + mAb in B-cell driven lymphoma Ar

Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, the first known therapy within the emerging deep B-cell depletion category to receive this designation in RA Company to host webcast later this morning to discuss initial safety and translational data from clinical trials evaluating AlloNK in combination with anti-CD20 monoclonal antibodies across autoimmune diseases; presentation to also include outpatient feasibility and tolerability observations Initial clinical response data in refractory RA expected in the first half of 2026, with FDA dis

The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy, highlighting a favorable tolerability profile observed to date and the feasibility of patient management in outpatient rheumatology clinics Initial translational data highlighting uniform, consistent, deep B-cell depletion supporting AlloNK's intended mechanism of action SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devast

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) --  Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate at the following investor conferences: TD Cowen's Immunology & Inflammation Summit (Virtual) - fireside chat on Wednesday, November 12, 2025, at 11:30 a.m. ET 2025 Jefferies Global Healthcare Conference in London - fireside chat on Tuesday, November 18, 2025, at 12:00 p.m. GMT The Artiva management team will also be available to participate in investor meetings with investors

Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development  FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate in the deep B-cell depleting category to receive this designation with the potential to become the first in the category to advance to a pivotal trial in RA, pending FDA feedback expected in 1H 2026 Continued execution and enrollment progress with more than 20 patients treated with AlloNK + monoclonal antibody (mAb) therapy across company-sponsored and investigator-initiated trials in autoimmune diseases Upcoming translational data release expected to show uniform, consistent, deep B-cell d

8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

EFFECT - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

S-3 - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

S-8 - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

H.C. Wainwright resumed coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $12.00

H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

Cantor Fitzgerald initiated coverage of Artiva Biotherapeutics with a rating of Overweight and set a new price target of $23.00

TD Cowen initiated coverage of Artiva Biotherapeutics with a rating of Buy

Wedbush initiated coverage of Artiva Biotherapeutics with a rating of Outperform and set a new price target of $18.00

Needham initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $23.00

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation. "We are delighted to welcome Thad to Artiva as he brings strong late-stage development and comme

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis. "We are thrilled to welcome Elaine to Artiva's board at such an imp

– 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding – Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials     COVENTRY, England, Jan. 8, 2026 /PRNewswire/ -- NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, today announced the appointment of Thomas J. Farrell as Chief Executive Officer and Director. Tom succeeds company founder Joe Healey, who will remain involved in the company, ensuring continuity and o

IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog

SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13D - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13D - Artiva Biotherapeutics, Inc. (0001817241) (Subject)